Antiproliferative Activity of Lignans from Olea ferruginea: In Vitro Evidence Supported by Docking Studies

Front Biosci (Landmark Ed). 2023 Sep 24;28(9):216. doi: 10.31083/j.fbl2809216.

Abstract

Background: The aim of the current study was to investigate the anticancer potential of bioactive compounds isolated from the leaves of Olea ferruginea (O. ferruginea). Lignans from O. ferruginea were previously described to possess antibacterial, antileishmanial, and antioxidant properties. Nevertheless, the antiproliferative activity of cycloolivil (1), ferruginan (2), and ferruginan A (3) have not been investigated in depth.

Methods: The compounds were isolated from the ethyl acetate fraction of the leaves extract of O. ferruginea. The isolated molecules were evaluated for their anticancer activity against U-87 MG malignant glioma cells. In parallel, molecular docking studies were also performed to investigate the interaction of the compounds with a duplex DNA sequence and epidermal growth factor receptor (EGFR).

Results: In vitro tests showed that all three compounds inhibit U-87 MG malignant glioma cell proliferation dose-dependently in the µM range, and ferruginan A (3) was highlighted as the most promising compound of the set. Molecular docking studies showed that the compounds could interfere with double stranded DNA possessing a cisplatin 1,2-d(GpG) intrastrand cross-link and EGFR.

Conclusions: Overall, the findings suggest that the tested compounds from O. ferruginea may represent a starting point for the identification of novel tools to inhibit glioma cell proliferation.

Keywords: EGFR; Olea ferruginea; cycloolivil; docking; ferruginan; glioma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ErbB Receptors
  • Glioma*
  • Lignans* / pharmacology
  • Molecular Docking Simulation
  • Olea*
  • Plant Extracts / pharmacology

Substances

  • Lignans
  • Plant Extracts
  • ErbB Receptors